NASDAQ:ARDX - Ardelyx Stock Price, Forecast & News

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.37). The biopharmaceutical company earned $3.01 million during the quarter. View Ardelyx's Earnings History.

Ardelyx is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Ardelyx.

4 analysts have issued 1-year price objectives for Ardelyx's stock. Their forecasts range from $9.00 to $15.00. On average, they anticipate Ardelyx's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 50.7% from the stock's current price. View Analyst Price Targets for Ardelyx.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.

Media coverage about ARDX stock has trended extremely negative on Wednesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ardelyx earned a coverage optimism score of -4.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Ardelyx.

Ardelyx saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,940,000 shares, an increase of 42.8% from the December 31st total of 2,760,000 shares. Based on an average daily trading volume, of 890,800 shares, the short-interest ratio is currently 4.4 days. Approximately 6.3% of the company's stock are sold short. View Ardelyx's Current Options Chain.

Some companies that are related to Ardelyx include Pacira Biosciences (PCRX), Insmed (INSM), Arvinas (ARVN), Akcea Therapeutics (AKCA), Tricida (TCDA), Forty Seven (FTSV), Alder Biopharmaceuticals (ALDR), Ligand Pharmaceuticals (LGND), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Esperion Therapeutics (ESPR), Innoviva (INVA), Amneal Pharmaceuticals (AMRX) and BELLUS Health (BLUSF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), Rigel Pharmaceuticals (RIGL), Micron Technology (MU), Viking Therapeutics (VKTX), BioCryst Pharmaceuticals (BCRX), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP).

Ardelyx's stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (24.52%), California Public Employees Retirement System (0.13%), Strs Ohio (0.07%) and SG Americas Securities LLC (0.02%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Mark Kaufmann, Michael Raab and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.

ARDX stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, California Public Employees Retirement System, Strs Ohio and SG Americas Securities LLC. View Insider Buying and Selling for Ardelyx.

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARDX stock can currently be purchased for approximately $7.30.

Ardelyx has a market capitalization of $480.35 million and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-91,300,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Ardelyx employs 86 workers across the globe.View Additional Information About Ardelyx.

The official website for Ardelyx is http://www.ardelyx.com/.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]